このエントリーをはてなブックマークに追加
ID 61307
FullText URL
Author
Sugiura, Hiroyuki Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nishimori, Hisakazu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Nishii, Kazuya Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Toji, Tomohiro Department of Pathology, Okayama University Hospital
Fujii, Keiko Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Fujii, Nobuharu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons researchmap
Matsuoka, Ken-ichi Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID
Nakata, Koh Department of Bioscience Medical Research Center, Niigata University Medical & Dental Hospital
Kiura, Katsuyuki Department of Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
Maeda, Yoshinobu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Abstract
Pulmonary alveolar proteinosis (PAP) is an uncommon lung disorder characterized by the excessive accumulation of surfactant-derived lipoproteins in the pulmonary alveoli and terminal bronchiole. Secondary PAP associated with primary myelofibrosis (PMF) is extremely rare, and to our knowledge, no autopsy case has been reported. We herein report an autopsy case of secondary PAP occurring in a patient with PMF who was treated with the Janus kinase 1/2 inhibitor ruxolitinib. We confirmed a diagnosis of PAP with complications based on the pathological findings at the autopsy. Notably, this case might suggest an association between ruxolitinib treatment and PAP occurrence.
Keywords
pulmonary alveolar proteinosis
primary myelofibrosis
autopsy
ruxolitinib
Published Date
2020-08-15
Publication Title
Internal Medicine
Volume
volume59
Issue
issue16
Start Page
2023
End Page
2028
ISSN
0918-2918
NCID
AA10827774
Content Type
Journal Article
language
英語
OAI-PMH Set
岡山大学
Copyright Holders
© 2020 by The Japanese Society of Internal Medicine
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.2169/internalmedicine.4082-19
License
https://creativecommons.org/licenses/by-nc-nd/4.0/